The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City and Wichita, the University of Kansas-Lawrence, and the Stowers Institute for Medical Research (via consortium agreement). In 2010, 143 members of KUCC accounted for $11.4 million of NCI funding and a total of $55.1 million in overall cancer-related funding. KUCC is led by Roy A. Jensen, M.D. who is supported by a strong, nationally recognized leadership team. Over the last seven years substantial progress has been made securing institutional commitment, recruiting key leadership positions, building nationally significant research programs, developing our clinical research program, improving and expanding our facilities, and creating transdisciplinary and collaborative interactions. With input from our External Advisory Board, we have established three goals for KUCC that will insure we make a national impact in the fight against cancer: Goal 1: Become the leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies. Goal 2: Provide the optimal environment for basic, translational, clinical, and population-based research in oncology by developing and fostering a collaborative, collegial, and dynamic culture of scientific inquiry. Goal 3: Be a nationally recognized leader in partnering with community oncologists and other key stakeholders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout our service area. To accomplish these goals KUCC has four research programs including: Cancer Biology, Cancer Control and Population Health, Cancer Prevention, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, the Cancer Center supports four shared resources: Biostatistics and Informatics, Lead Development and Optimization, Biospecimen, and Clinical Trials Management.
KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. We hope to establish an NCI-designated cancer center to meet the needs of the more than five million Americans who live within the 120,000 square miles of our catchment area.
|Atay, Safinur; Wilkey, Daniel W; Milhem, Mohammed et al. (2018) Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers. Mol Cell Proteomics 17:495-515|
|Kasemeier-Kulesa, Jennifer C; Romine, Morgan H; Morrison, Jason A et al. (2018) NGF reprograms metastatic melanoma to a bipotent glial-melanocyte neural crest-like precursor. Biol Open 7:|
|Del Castillo, Erika; Meier, Richard; Chung, Mei et al. (2018) The Microbiomes of Pancreatic and Duodenum Tissue Overlap and are Highly Subject Specific but Differ between Pancreatic Cancer and Non-Cancer Subjects. Cancer Epidemiol Biomarkers Prev :|
|Cupertino, Ana Paula; Cartujano-Barrera, Francisco; Perales, Jaime et al. (2018) ""Vive Sin Tabaco… ¡Decídete!"" Feasibility and Acceptability of an e-Health Smoking Cessation Informed Decision-Making Tool Integrated in Primary Healthcare in Mexico. Telemed J E Health :|
|Neums, Lisa; Suenaga, Seiji; Beyerlein, Peter et al. (2018) VaDiR: an integrated approach to Variant Detection in RNA. Gigascience 7:|
|Preet, Ranjan; Dixon, Dan A (2018) Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment. Cell Mol Gastroenterol Hepatol 5:647-648|
|Tomilin, Viktor; Reif, Gail A; Zaika, Oleg et al. (2018) Deficient transient receptor potential vanilloid type 4 function contributes to compromised [Ca2+]i homeostasis in human autosomal-dominant polycystic kidney disease cells. FASEB J 32:4612-4623|
|Raman, Archana; Parnell, Stephen C; Zhang, Yan et al. (2018) Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease. Am J Physiol Renal Physiol :|
|Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782|
|Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163|
Showing the most recent 10 out of 177 publications